Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON: Ipilimumab and Nivolumab in HR+ Breast Cancer
NCT03409198Phase 2Completed
- Sponsor
- Oslo University Hospital
- Start
- Jan 2018
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of ipilimumab and nivolumab in Hormone-Receptor-Positive Breast Cancer (2 arms), sponsored by Oslo University Hospital. Primary endpoints: Toxicity at 3 years and Progression-free survival at 3 years. Started Jan 2018; status: completed.
02
Drugs
ipilimumabnivolumab
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT03409198.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409198.